{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:42:13Z","timestamp":1793954533292,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.eclinm.2023.102394","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T07:51:49Z","timestamp":1703231509000},"page":"102394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study"],"prefix":"10.1016","volume":"67","author":[{"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon G.","family":"Busbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Pieramici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Danzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-4370","authenticated-orcid":false,"given":"Brian C.","family":"Joondeph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James C.","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Turpcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3433-8432","authenticated-orcid":false,"given":"Szil\u00e1rd","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102394_bib1","volume":"vol. 359","author":"Dunbar","year":"2018"},{"key":"10.1016\/j.eclinm.2023.102394_bib2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14712598.2022.2121646","article-title":"Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques","volume":"22","author":"Kovacs","year":"2022","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.eclinm.2023.102394_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.eclinm.2023.102394_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.eclinm.2023.102394_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071473","article-title":"Novel treatments for age-related macular degeneration: a review of clinical advances in sustained Drug delivery systems","volume":"14","author":"Jim\u00e9nez-G\u00f3mez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.eclinm.2023.102394_bib6","volume":"vol. 12","author":"Flores","year":"2021"},{"key":"10.1016\/j.eclinm.2023.102394_bib7","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.eclinm.2023.102394_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1167\/tvst.10.1.34","article-title":"Long-term safety evaluation of continuous intraocular delivery of aflibercept by the intravitreal gene therapy candidate ADVM-022 in nonhuman primates","volume":"10","author":"Kiss","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.eclinm.2023.102394_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.943915","article-title":"Application and mechanism of anti-VEGF drugs in age-related macular degeneration","volume":"10","author":"Song","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.eclinm.2023.102394_bib10","first-page":"87","article-title":"A\u00a0retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK","volume":"10","author":"Hykin","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.eclinm.2023.102394_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.eclinm.2023.102394_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jop.2021.0001","article-title":"Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema","volume":"37","author":"Gelfman","year":"2021","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.eclinm.2023.102394_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.eclinm.2023.102394_bib14","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.eclinm.2023.102394_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","article-title":"Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents","volume":"138","author":"Evans","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.eclinm.2023.102394_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In\u00a0vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eclinm.2023.102394_bib17","series-title":"Expanding the potential of adeno-associated virus for the treatment of intractable inherited retinal degenerations. [Doctoral dissertation]","author":"Day","year":"2017"},{"key":"10.1016\/j.eclinm.2023.102394_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT 01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eclinm.2023.102394_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajo.2019.03.006","article-title":"Three-year follow-up of phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age-related macular degeneration","volume":"204","author":"Rakoczy","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.eclinm.2023.102394_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.eclinm.2023.102394_bib21","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4103\/1673-5374.306063","article-title":"The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery","volume":"16","author":"Ross","year":"2021","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.eclinm.2023.102394_bib22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.eclinm.2023.102394_bib23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","article-title":"Seeing the light after 25 Years of retinal gene therapy","volume":"24","author":"Trapani","year":"2018","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.eclinm.2023.102394_bib24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/jamaophthalmol.2020.3989","article-title":"Lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration","volume":"138","author":"Finger","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.eclinm.2023.102394_bib25","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2147\/OPTH.S88624","article-title":"Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration","volume":"9","author":"Khanani","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.eclinm.2023.102394_bib26","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/IAE.0000000000002668","article-title":"Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections","volume":"40","author":"Starr","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.eclinm.2023.102394_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors\u2013implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.eclinm.2023.102394_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.10.4.3","article-title":"Inflammation in viral vector-mediated ocular gene therapy: a review and report from a workshop hosted by the foundation fighting blindness, 9\/2020","volume":"10","author":"Chan","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.eclinm.2023.102394_bib29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/bjo.2009.174912","article-title":"Gene therapy for ocular diseases","volume":"95","author":"Liu","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102394_bib30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","article-title":"Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol","volume":"125","author":"Adrean","year":"2018","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102394_bib31","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1007\/s00417-021-05283-0","article-title":"Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence","volume":"259","author":"Adrean","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023005710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023005710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:24:06Z","timestamp":1762899846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023005710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"alternative-id":["S2589537023005710"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102394","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102394"}}